论文部分内容阅读
目的:探讨分析替加环素辅助治疗ICU患者多重耐药菌感染的临床疗效。方法:选择2015年4月至2017年4月间我院接治的130例感染多重耐药菌的ICU患者,按照随机、对照、平行的设计原则分为两组。对照组65例,应用头孢哌酮钠-舒巴坦钠治疗;治疗组65例,在对照组基础上再应用替加环素辅助治疗。治疗时间为2w,比较两组疗效以及症状改善时间。结果:治疗组的总有效率为92.31%,体温改善时间为(3.64±1.18)d,胸部X线片改善时间为(11.97±4.03)d,肺部啰音改善时间为(7.51±2.09)d,CRP改善时间为(4.67±1.15)d,均优于对照组,差异具统计学意义(P<0.05)。结论:替加环素辅助治疗ICU患者多重耐药菌感染的临床疗效显著,值得推广应用。
Objective: To investigate the clinical efficacy of tigecycline in the treatment of multiple drug-resistant bacterial infections in ICU patients. Methods: A total of 130 ICU patients infected with multidrug-resistant bacteria in our hospital from April 2015 to April 2017 were divided into two groups according to randomized, controlled and parallel design principles. Control group of 65 cases, the application of cefoperazone sodium - sulbactam sodium treatment group of 65 patients on the basis of the control group and then applied tigecycline adjuvant therapy. The treatment time was 2w, the curative effect and symptom improvement time of the two groups were compared. Results: The total effective rate was 92.31% in the treatment group, 3.64 ± 1.18 days in the body temperature, 11.97 ± 4.03 days in the chest radiograph, and 7.51 ± 2.09 days in the pulmonary rales. , And the improvement time of CRP was (4.67 ± 1.15) d, both of which were better than that of the control group. The difference was statistically significant (P <0.05). Conclusion: The clinical efficacy of tigecycline in the treatment of multiple drug-resistant bacterial infections in ICU patients is significant and should be widely applied.